The applications and advances of artificial intelligence in drug regulation: A global perspective
Применение и достижения искусственного интеллекта в регулировании лекарственных средств: глобальная перспектива
2024-11-13
SCID: 54.1/78mczmc7
Discuss with AI
artificial intelligencedrug regulationregulatory agenciesregulatory decision-makingsafety surveillance
Figures from the paper
Abstract (AI)
Artificial intelligence (AI) has emerged as a transformative force in healthcare, with applications spanning diagnostics to drug development. However, its integration into drug regulation remains nascent, with varying degrees of adoption and implementation across different regulatory bodies worldwide. This review aims to provide a comprehensive overview of the current state of AI in drug regulation, encapsulating AI-related policies, initiatives, and its practical application in regulatory agencies globally. It further discusses the challenges and future prospects of AI in this field. The findings reveal that numerous agencies have launched action plans and initiatives to incorporate AI, aiming to streamline regulatory processes and enhance data-driven regulatory decision-making. Moreover, AI's deployment in safety surveillance, workflow optimization, and regulatory science research is expanding, highlighting its increasing impact on drug regulation. Nonetheless, key challenges persist, such as data quality and reliability, technical limitations, talent shortage and the absence of standards. The review concludes that interdisciplinary collaboration is crucial to harness AI's full potential in drug regulation and overcoming its current limitations. In the future, AI may become a pivotal catalyst in drug regulation, promising a new era of enhanced scrutiny, efficiency, and innovation that will benefit public health on a global scale.
Key Findings
1
AI adoption in drug regulation remains nascent and varies substantially among regulatory bodies worldwide.
2
AI deployment is expanding in safety surveillance, workflow optimization, and regulatory science research, increasing its practical impact.
3
Interdisciplinary collaboration is identified as essential for overcoming current limitations and realizing AI’s potential to improve regulatory scrutiny, efficiency, and innovation.
4
Numerous regulatory agencies have launched AI action plans and initiatives to streamline processes and strengthen data-driven decision-making.
5
Persistent barriers include inadequate data quality and reliability, technical limitations, shortages of skilled personnel, and absent standards.
Research Object
Artificial intelligence integration into global drug regulation and regulatory agencies
Research Subject
AI-related policies, initiatives, applications, benefits, challenges, and future prospects in drug regulation, including safety surveillance, workflow optimization, and data-driven decision-making
Publication Details
Publication Date
2024-11-13
Journal
Publisher
ISSN
Cited by
61
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest